Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neuroblastoma.

B H Kushner1, N K Cheung

  • 1Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021.

Pediatric Annals
|April 1, 1988
PubMed
Summary
This summary is machine-generated.

Identifying prognostic factors guides cancer therapy. While intensive treatments improve remission, microscopic disease and toxic therapies limit cures, necessitating trials for novel immunotherapies against residual cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A prediction model for return to work after injury in Hong Kong: abridged secondary publication.

Hong Kong medical journal = Xianggang yi xue za zhi·2022
Same author

Trajectory of functional outcome and health status after moderate-to-major trauma in Hong Kong: A prospective 5 year cohort study.

Injury·2019
Same author

Trauma team activation criteria and outcomes of geriatric trauma: 10 year single centre cohort study.

The American journal of emergency medicine·2018
Same author

Vascularized Tissue-Engineered Model for Studying Drug Resistance in Neuroblastoma.

Theranostics·2017
Same author

Acute myeloid leukemia targets for bispecific antibodies.

Blood cancer journal·2017
Same author

Acute myeloid leukemia targets for bispecific antibodies.

Blood cancer journal·2017
Same journal

Management of Menstrual Disorders in Adolescents of All Abilities.

Pediatric annals·2026
Same journal

The Intersection of Weight Management and Eating Disorders.

Pediatric annals·2026
Same journal

Recognizing and Responding to Complexity in the Medical Care of Adolescents.

Pediatric annals·2026
Same journal

Language Development in Bilingual Children: A Pediatrician's Guide.

Pediatric annals·2026
Same journal

Navigating Identification and Management of Substance Use in Adolescents.

Pediatric annals·2026
Same journal

Risks and Benefits of Social Media on Adolescent Health.

Pediatric annals·2026
See all related articles

Area of Science:

  • Oncology
  • Immunology
  • Cancer Therapeutics

Background:

  • Prognostic factor identification aids personalized cancer treatment strategies.
  • Current intensive therapies (chemotherapy, radiation, surgery) improve remission rates for widespread disease.
  • Microscopic residual disease and the limitations of highly toxic myeloablative therapies hinder long-term cures, particularly in poor-risk patients.

Purpose of the Study:

  • To review the impact of prognostic factors on cancer therapy selection.
  • To evaluate the effectiveness of current multimodal treatments against widespread and microscopic disease.
  • To explore the potential of novel biological therapies, specifically immune-mediated tumor cytotoxicity, in addressing treatment-resistant microscopic disease.

Main Methods:

Related Experiment Videos

  • Review of existing literature on prognostic factors in cancer.
  • Analysis of outcomes from intensive chemotherapy, radiation, and surgical interventions.
  • Examination of emerging research on biological therapies and immune-mediated cytotoxicity.

    • Main Results:

    • Prognostic factors enable rational therapy choices for individual patients.
    • Intensive treatments have increased remission rates but not eradicated microscopic disease.
    • Novel biological therapies offer insights into immune-mediated tumor killing mechanisms.

    Conclusions:

    • Despite advances, microscopic residual cancer remains a significant challenge for long-term survival.
    • Highly toxic myeloablative therapies show limited efficacy in improving cure rates for poor-risk patients.
    • Clinical trials are crucial to assess the role of novel immunotherapies in adjuvant treatment for occult microscopic disease.